The 41-year-old female, who was diagnosed with SLE 20 years ago, developed diffuse large B cell lymphoma (DLBCL), and was enrolled in a clinical trial using BCMA/CD19 dual-targeted CAR-T therapy due to side effects of standard R-CHOP chemotherapy. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.